Rifaximin is an oral antibiotic indicated for travelers' diarrhea. Rifaximin pharmacokinetics were evaluated in individuals challenged with Shigella flexneri. Peak plasma rifaximin concentrations were low after 9 consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers.
At the onset of illness (i.e., diarrhea plus ≥1 enteric symptom), oral rifaximin 200 mg was administered every 8 hours for 3 days for a total of 9 doses. Volunteers remained in the inpatient research facility at least through day 7 to be monitored for signs and symptoms of shigellosis and other adverse events. During rifaximin treatment, volunteers were administered a 3-day course of oral ciprofloxacin 500 mg twice daily to eradicate S. flexneri if an individual developed shigellosis and did not respond to 3 doses of rifaximin. Individuals who began ciprofloxacin therapy completed the full 9-dose course of rifaximin. Volunteers were discharged after ciprofloxacin treatment was initiated, clinical assessments were complete, and 2 negative stool cultures for S.
flexneri were obtained.
Blood samples for evaluation of rifaximin pharmacokinetics were collected on day 1 (pre-challenge); immediately before the 3rd, 5th, 7th, and 9th rifaximin doses; serially at 0.5, 1, 1.5, 2, 4, 6, and 8 hours after the 3rd and 9th doses; and additionally at 12, 16, 20, and 24 hours after the 9th dose. Plasma concentrations of rifaximin were measured by reverse-phase high performance liquid chromatography with tandem quadrupole mass spectrometric detection, with a lower limit of quantitation of 0.5 ng/ml. Subjects were eligible for pharmacokinetic evaluation if they developed shigellosis, they received 9 consecutive doses of rifaximin, and sufficient plasma concentration data were Fifteen healthy volunteers were enrolled in the study and challenged with S.
A C C E P T E D
flexneri. Thirteen individuals met criteria for rifaximin treatment (i.e., developed shigellosis), received at least 1 dose of study medication, and were included in the pharmacokinetic and safety populations: 12 received all 9 doses of rifaximin and 1 received 8 doses. Of the 13 volunteers who received rifaximin, 9 were male (69%) and 4 were female (31%). The mean age of volunteers was 32.5 years (range, 18 to 45 years). All 13 individuals developed ≥1 symptom of shigellosis; the predominant symptoms were abdominal pain (100%), headache (85%), and diarrhea (77%). Eight volunteers received rescue therapy with ciprofloxacin.
Rifaximin administration did not result in any clinically relevant changes in pharmacokinetic parameters (Table 1 and Fig. 1 ). After repeated administration of oral rifaximin 200 mg, the mean C max values for rifaximin were 1.63 ± 0.86 ng/ml on day 1 (3 rifaximin concentrations was comparable after 3 and 9 consecutive rifaximin doses (0.81 to 3.40 ng/ml and 0.68 to 2.26 ng/ml, respectively), and there were no differences in mean rifaximin plasma concentrations after repeated dosing (Fig. 1A and 1B) . 

